Aurora Asks Regulator to Force Curaleaf to Fix Hostile Bid Deficiencies
ACB sits 62% above its 52-week low of $2.56.
Summary
Aurora Cannabis has escalated its defense against Curaleaf's hostile takeover by filing an application with the Alberta Securities Commission, seeking an order to compel Curaleaf to correct deficiencies in its bid circular. The company alleges Curaleaf failed to provide pro forma financial statements, did not hold the bid open for the required 105-day period, and omitted a French-language notice, all of which Aurora says deprive shareholders of information and time needed to evaluate the offer. Aurora also claims Curaleaf's bid does not qualify as a permitted bid under its Shareholder Rights Plan, meaning the plan would be triggered if Curaleaf acquires more than 20% of shares. This follows Aurora's September 2 directors' circular unanimously recommending rejection of the bid, and its earlier rebuttals of Curaleaf's claims. The regulatory filing adds a new legal front that could delay or complicate Curaleaf's bid, potentially strengthening Aurora's position. The ASC's decision on the application will be a key near-term catalyst for the stock.
At the time of this announcement, ACB was trading at $4.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $273.6M. The 52-week trading range was $2.56 to $6.67. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.